v3.26.3
Stockholders' Equity
9 Months Ended
Sep. 30, 2026
Stockholders’ Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 12 - STOCKHOLDERS’ EQUITY:

 

a. Stock -based compensation

 

Below is a table summarizing all the grants of restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) to employees made during the nine months ended September 30, 2026.

 

    No. of RSUs and RSAs
granted
    Exercise
price
    Vesting
period
    Fair value
at grant (*)
 
Employees     2,120,056       -       (** )   $ 9,585  

 

(*) The RSUs’ and RSAs’ fair value is based on the Company’s share price on the Nasdaq Capital Market on the grant dates.

 

(**) Includes 490,341 RSUs and 1,629,715 RSAs. Of the RSUs, 478,341 vest in 8 equal quarterly installments starting April 1, 2026, and 12,000 vest as follows: 4,000 on January 1, 2027 and the remaining 8,000 in 8 equal quarterly installments starting April 1, 2027. For the RSAs’ vesting terms, see below.

 

Performance restricted stock units (“PSUs”) granted

 

On December 31, 2025, the Company granted 166,000 PSUs representing a right to receive shares of the Company’s common stock to executive officers of the Company. The PSUs vest upon the satisfaction of certain performance conditions or certain market conditions.

 

The total fair value of these PSUs on the date of grant was $473, using the quoted closing market share price of $2.85 on the Nasdaq Capital Market on the date of grant.

 

During January 2026, the applicable market condition related to 166,000 PSUs previously granted to the Company’s executive officers was satisfied. As a result, the Company recognized stock-based compensation expense of $469 during the nine months ended September 30, 2026, based on the fair value determined using the quoted closing market share price of $2.85 on the Nasdaq Capital Market on the date of grant.

 

Net-Settlement of RSUs

 

In March 2026, an aggregate of 959,803 RSUs that had vested in prior years, originally granted to executives under Section 3(i) of the Israeli Income Tax Ordinance, were settled on a net-settlement basis for tax withholding purposes. As a result, 479,902 RSUs were withheld and returned to the Company’s equity incentive plan pool, and 479,901 shares of common stock were issued to the executives. The cash settlement of the related withholding tax obligation, in the aggregate amount of $1,750, is reflected within “Tax withholdings related to stock-based compensation settlements” in the consolidated statements of changes in stockholders’ equity. This amount includes an additional tax payment of $231 made in April 2026 following an adjustment of the related tax withholding obligation.

 

In May 2026, an aggregate of 59,625 RSUs that had vested, originally granted to executives under Section 3(i) of the Israeli Income Tax Ordinance, were settled on a net-settlement basis for tax withholding purposes. As a result, 29,813 RSUs were withheld and returned to the Company’s equity incentive plan pool, and 29,812 shares of common stock were issued to the executives. The cash settlement of the related withholding tax obligation, in the amount of $121, is reflected within “Tax withholdings related to stock-based compensation settlements” in the consolidated statements of changes in stockholders’ equity.

 

In July 2026, an aggregate of 41,875 RSUs that had vested, originally granted to executives under Section 3(i) of the Israeli Income Tax Ordinance, were settled on a net-settlement basis for tax withholding purposes. As a result, 20,938 RSUs were withheld and returned to the Company’s equity incentive plan pool, and 20,937 shares of common stock were issued to the executives. The cash settlement of the related withholding tax obligation, in the amount of $88, is reflected within “Tax withholdings related to stock-based compensation settlements” in the consolidated statements of changes in stockholders’ equity.

 

Exercise of Stock Options

 

In July 2026, options to purchase 50,000 shares of the Company’s common stock were exercised at an exercise price of $3.69 per share, for aggregate cash proceeds of $184. The proceeds are reflected within “Exercise of stock options” in the consolidated statements of changes in stockholders’ equity and within “Proceeds from exercise of stock options” in the consolidated statements of cash flows.

 

RSAs granted

 

On September 24, 2026, the Company granted 1,629,715 RSAs to executive officers of the Company. The RSAs were issued as shares of the Company’s common stock on the grant date and are subject to forfeiture until vested. Holders of unvested RSAs are entitled to nonforfeitable dividends.

 

Of the RSAs granted, 1,031,734 vested immediately on the grant date, and the remaining 597,981 vest in 8 equal quarterly installments starting October 1, 2026 and ending July 1, 2028. The total fair value of these RSAs on the date of grant was $7,806, using the quoted closing market share price of $4.79 on the Nasdaq Capital Market on the date of grant.

 

Of the RSAs granted presented above, 633,077 fully vested RSAs were granted to three executive officers in exchange for the cancellation of an aggregate of 1,418,499 outstanding stock options held by them (the “Option Exchange”). The number of RSAs granted in the Option Exchange was determined based on the fair value of the cancelled options. The Option Exchange was accounted for as a modification in accordance with ASC 718, “Compensation—Stock Compensation”. Because the fair value of the RSAs granted did not exceed the fair value of the cancelled options immediately before the modification, the Option Exchange did not result in incremental compensation cost.

 

b. Dividends to Shareholders

 

On December 31, 2025, the Company’s Board of Directors declared a special cash dividend of $0.25 per share of common stock, payable to holders of record as of the close of business on January 16, 2026. In accordance with the terms of the Company’s outstanding warrant agreements, holders of 20,000 warrants as of the record date were also entitled to receive a cash payment of $0.25 per underlying warrant share. Holders of RSUs granted prior to the record date, including unvested RSUs, were entitled to receive a dividend equivalent of $0.25 per RSU unit, payable upon vesting of the underlying awards. The aggregate dividend and dividend equivalent amount, including amounts attributable to outstanding warrants and unvested RSUs, totaled $10,870.

 

Dividend equivalents declared on unvested RSUs are subject to the same vesting conditions as the underlying awards and are forfeited if the awards do not vest. Such dividend equivalents are deferred and will be paid to RSU holders upon vesting of the underlying award. In accordance with ASC 718, forfeitable dividend equivalents on equity-classified awards are recognized as a charge to retained earnings at the date of declaration, with a corresponding liability recorded in dividends payable.

 

During the nine months ended September 30, 2026, the Company paid dividends of $10,061 to its shareholders, together with dividend equivalents of $433 to RSU holders and $5 to warrant holders. In addition, dividend equivalents of $5 were forfeited in connection with the forfeiture of the underlying RSUs upon a director’s departure.

 

As of September 30, 2026, dividends payable of $366 were recorded in the consolidated balance sheets.